Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.53 |
| ▸ | PLK4 | O00444 | 2/20 | 0.49 |
| ▸ | PAK4 | O96013 | 2/20 | 0.49 |
| ▸ | PDE2A | O00408 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | SGK1 | O00141 | 2/20 | 0.42 |
| ▸ | PAK1 | Q13153 | 6/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.39 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29705692 | 0.94 | HPGDS (0.61) | HPGDSPLK4PAK4PDE2AHTR2A | |
| SCHEMBL22282069 | 0.94 | HPGDS (0.61) | HPGDSPLK4PAK4PDE2AHTR2A | |
| SCHEMBL22281549 | 0.92 | HPGDS (0.60) | HPGDSPLK4PAK4PDE2AHTR2A | |
| SCHEMBL3755106 | 0.88 | PLK4 (0.43) | HPGDSPLK4PAK4PDE2ASGK1 | |
| SCHEMBL3755112 | 0.88 | PLK4 (0.43) | HPGDSPLK4PAK4PDE2ASGK1 | |
| Hydrochloric Acid SCHEMBL22497005 | 0.82 | PLK4 (0.47) | HPGDSPLK4PAK4PDE2AHTR2A | |
| Hydrochloric Acid SCHEMBL22497004 | 0.82 | PLK4 (0.47) | HPGDSPLK4PAK4PDE2AHTR2A | |
| SCHEMBL13047997 | 0.81 | BTK (0.45) | PLK4PAK4SGK1PAK1 | |
| SCHEMBL8095697 | 0.78 | PLK4 (0.55) | HPGDSPLK4PAK4PDE2AHTR2A | |
| SCHEMBL28610635 | 0.77 | BTK (0.53) | PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298557-A1 | PYRAZOLOPYRIMIDINE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2010-11-25 | — | — | US | disclosed |
| US-20100298557-A1 | PYRAZOLOPYRIMIDINE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2010-11-25 | — | — | US | disclosed |
| US-20100298557-A1 | PYRAZOLOPYRIMIDINE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2010-11-25 | — | — | US | disclosed |
| EP-2123654-A1 | PYRAZOLOPYRIMIDINE COMPOUND | Taisho Pharmaceutical Co. Ltd. (JP) | 2009-11-25 | — | — | EP | disclosed |
| EP-2123654-A1 | PYRAZOLOPYRIMIDINE COMPOUND | Taisho Pharmaceutical Co. Ltd. (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298557-A1 | PYRAZOLOPYRIMIDINE COMPOUND | SYK, LCK, FYN | HPGDS 2823/4885PLK4 1106/4885PAK4 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.